pirinixic acid has been researched along with cardiovascular agents in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (75.00) | 29.6817 |
| 2010's | 1 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Benéteau, N; Chapuis, V; Colpaert, FC; Dupont-Passelaigue, E; Junquéro, D; Lestienne, F; Patoiseau, JF; Rival, Y; Taillandier, T | 1 |
| Huang, TH; Li, Y; Roufogalis, BD; Tran, VH | 1 |
| Banks, T; Oyekan, A | 1 |
| Biswal, S | 1 |
4 other study(ies) available for pirinixic acid and cardiovascular agents
| Article | Year |
|---|---|
Cardiovascular drugs inhibit MMP-9 activity from human THP-1 macrophages.
Topics: Acetamides; Acetates; Anilides; Cardiovascular Agents; Cell Line; Enzyme Inhibitors; Fatty Acids, Monounsaturated; Fenofibrate; Fluvastatin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lipoproteins, LDL; Macrophages; Matrix Metalloproteinase 9; Matrix Metalloproteinase Inhibitors; Mevalonic Acid; Monocytes; Pyrimidines; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Sterol O-Acyltransferase; Sulfonamides; Sulfonic Acids; Tetradecanoylphorbol Acetate; Thiazolidinediones; Tissue Inhibitor of Metalloproteinase-1; Transcription Factors | 2004 |
Gypenoside XLIX, a naturally occurring gynosaponin, PPAR-alpha dependently inhibits LPS-induced tissue factor expression and activity in human THP-1 monocytic cells.
Topics: Anti-Inflammatory Agents; Antineoplastic Agents, Phytogenic; Cardiovascular Agents; Cell Line; Dose-Response Relationship, Drug; Drugs, Chinese Herbal; Gynostemma; Humans; Indoles; Lipopolysaccharides; Monocytes; NF-kappa B; Peroxisome Proliferators; PPAR alpha; Promoter Regions, Genetic; Pyrimidines; Pyrrolidines; RNA, Messenger; Saponins; Thiocarbamates; Thromboplastin; Transcription, Genetic; Transfection | 2007 |
Peroxisome proliferator-activated receptor alpha activation attenuated angiotensin type 1-mediated but enhanced angiotensin type 2-mediated hemodynamic effects to angiotensin II in the rat.
Topics: Angiotensin II; Animals; Cardiovascular Agents; Clofibrate; Fenofibrate; Hemodynamics; Male; Models, Animal; Nitric Oxide; PPAR alpha; Pyrimidines; Rats; Rats, Sprague-Dawley; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2 | 2008 |
Novel cardiovascular drugs in clinical trials.
Topics: Anticholesteremic Agents; Benzaldehydes; Cardiovascular Agents; Cardiovascular Diseases; Clinical Trials as Topic; Endothelin Receptor Antagonists; Fibrinolytic Agents; Humans; Immunologic Factors; Isoxazoles; Lipoxygenase Inhibitors; Metalloendopeptidases; Oxazolidinones; Oximes; Phospholipase A2 Inhibitors; Probucol; Pyrimidines; Quinolines; Thiophenes | 2010 |